Skip to main content
Erschienen in: Acta Neuropathologica 5/2018

26.09.2018 | Correspondence

cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

verfasst von: Daniel J. Brat, Kenneth Aldape, Howard Colman, Eric C. Holland, David N. Louis, Robert B. Jenkins, B. K. Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp, Andreas von Deimling, Michael Weller

Erschienen in: Acta Neuropathologica | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Excerpt

The World Health Organization (WHO) central nervous system tumor classification represents the primary source of updates on diagnostic classes, grades and criteria [17]. However, recent and ongoing advances in our understanding of brain tumor molecular pathogenesis warrant more rapid integration of this information into clinical practice between WHO updates. To accomplish this, cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established in 2016 [15, 16]. Since then, cIMPACT-NOW has convened three separate working committees to address classification and grading questions and challenges. Working Committee 1 focused on a concern that the classification and grading of Isocitrate Dehydrogenase (IDH)-wildtype diffuse astrocytic gliomas do not reflect our current understanding of the molecular pathogenesis and clinical outcomes associated with these tumors. …
Literatur
9.
Zurück zum Zitat Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718. https://doi.org/10.1007/s00401-010-0781-z CrossRefPubMed Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718. https://​doi.​org/​10.​1007/​s00401-010-0781-z CrossRefPubMed
16.
Zurück zum Zitat Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 27:851–852. https://doi.org/10.1111/bpa.12457 CrossRefPubMed Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 27:851–852. https://​doi.​org/​10.​1111/​bpa.​12457 CrossRefPubMed
17.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system. Intl. Agency for Research, City Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system. Intl. Agency for Research, City
27.
Zurück zum Zitat Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M et al (2018) Distribution of EGFR amplification, combined 7gain and 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol (in press), Doi. https://doi.org/10.1007/s00401-018-1905-0 CrossRef Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M et al (2018) Distribution of EGFR amplification, combined 7gain and 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol (in press), Doi. https://​doi.​org/​10.​1007/​s00401-018-1905-0 CrossRef
32.
Zurück zum Zitat Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693. https://doi.org/10.1007/s00401-015-1409-0 CrossRefPubMed Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693. https://​doi.​org/​10.​1007/​s00401-015-1409-0 CrossRefPubMed
33.
Zurück zum Zitat Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959. https://doi.org/10.1007/s00401-017-1781-z CrossRefPubMed Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959. https://​doi.​org/​10.​1007/​s00401-017-1781-z CrossRefPubMed
Metadaten
Titel
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
verfasst von
Daniel J. Brat
Kenneth Aldape
Howard Colman
Eric C. Holland
David N. Louis
Robert B. Jenkins
B. K. Kleinschmidt-DeMasters
Arie Perry
Guido Reifenberger
Roger Stupp
Andreas von Deimling
Michael Weller
Publikationsdatum
26.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Acta Neuropathologica / Ausgabe 5/2018
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-018-1913-0

Weitere Artikel der Ausgabe 5/2018

Acta Neuropathologica 5/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.